Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

When does timing actually change outcomes in hidradenitis suppurativa? 

Dr. Brownstone walks through why earlier intervention with secukinumab may shift the trajectory, not just the symptoms.

In this overview, Nicholas Brownstone, MD, focuses on a post hoc analysis from the SUNSHINE and SUNRISE trials, looking at how disease duration and severity shape response to secukinumab. The signal is consistent: patients treated earlier in their disease course, particularly those with less advanced Hurley staging, were more likely to reach higher thresholds of response, including HiSCR100.  

It’s a useful reframing of a familiar challenge in HS. Not just whether a therapy works, but when it’s introduced, and what may be lost as disease progresses. Watch the breakdown, then explore the full poster for a closer look at the data.